Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Kedudukan dalam Saham #149
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and... Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Harga Saham
$59.43
Modal Pasaran
$121.03B
Perubahan (1 hari)
0.83%
Perubahan (1 tahun)
0.90%
Negara
US
Perdagangan Bristol-Myers Squibb Company (BMY)

Kategori

Nisbah P/E bagi Bristol-Myers Squibb Company (BMY)
Nisbah P/E pada March 2026 TTM: 17.10
Menurut laporan kewangan dan harga saham terkini Bristol-Myers Squibb Company, nisbah P/E semasa (TTM) ialah 17.10. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak -12.81.
Sejarah nisbah P/E bagi Bristol-Myers Squibb Company dari 2000 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) 17.10 9.52%
2025 15.61 -221.83%
2024 -12.81 -196.85%
2023 13.23 -45.39%
2022 24.22 22.34%
2021 19.80 -227.16%
2020 -15.57 -148.93%
2019 31.82 84.46%
2018 17.25 -82.77%
2017 100.10 356.89%
2016 21.91 -70.10%
2015 73.27 50.12%
2014 48.81 43.17%
2013 34.09 22.78%
2012 27.77 71.92%
2011 16.15 10.46%
2010 14.62 211.33%
2009 4.70 -46.38%
2008 8.76 -63.70%
2007 24.13 -25.86%
2006 32.55 117.67%
2005 14.95 -28.23%
2004 20.84 16.81%
2003 17.84 -17.56%
2002 21.64 5.71%
2001 20.47 -30.30%
2000 29.36 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
42.86 150.71%
US
28.47 66.50%
GB
21.88 28.00%
US
92.55 441.34%
US
20.85 21.95%
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.